A Randomized, Open-label, Single Dose, 2x4 Crossover Study to Evaluate the Safety and Pharmacokinetic Characteristics After Co-administration of JW0106 and C2101 and Administration of JW0107 in Healthy Volunteers Under Fasting Conditions
Latest Information Update: 18 Feb 2025
At a glance
- Drugs JW 0106+C 2101 (Primary) ; JW 0107 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors JW Pharmaceutical
Most Recent Events
- 18 Feb 2025 New trial record